[go: up one dir, main page]

WO2006113925A3 - Composition and use of phyto-percolate for treatment of disease - Google Patents

Composition and use of phyto-percolate for treatment of disease Download PDF

Info

Publication number
WO2006113925A3
WO2006113925A3 PCT/US2006/015302 US2006015302W WO2006113925A3 WO 2006113925 A3 WO2006113925 A3 WO 2006113925A3 US 2006015302 W US2006015302 W US 2006015302W WO 2006113925 A3 WO2006113925 A3 WO 2006113925A3
Authority
WO
WIPO (PCT)
Prior art keywords
phyto
percolate
disease
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/015302
Other languages
French (fr)
Other versions
WO2006113925A2 (en
Inventor
Tiffany Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zivo Bioscience Inc
Original Assignee
Health Enhancement Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/013375 external-priority patent/WO2005112987A2/en
Application filed by Health Enhancement Products Inc filed Critical Health Enhancement Products Inc
Priority to EP06758513A priority Critical patent/EP1928247A4/en
Priority to US12/067,735 priority patent/US8586053B2/en
Priority to CA002625818A priority patent/CA2625818A1/en
Publication of WO2006113925A2 publication Critical patent/WO2006113925A2/en
Priority to US11/606,676 priority patent/US7807622B2/en
Publication of WO2006113925A3 publication Critical patent/WO2006113925A3/en
Anticipated expiration legal-status Critical
Priority to US12/897,574 priority patent/US8791060B2/en
Priority to US14/558,516 priority patent/US10166270B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The invention further relates to the use of the phyto-percolate in a variety of disease states. The phyto-percolate is believed to contain an activity that induces the reduction of soluble and insoluble fibrin. Further, the phyto-percolate is believed to reduce oxidative stress in the body.
PCT/US2006/015302 2004-04-23 2006-04-20 Composition and use of phyto-percolate for treatment of disease Ceased WO2006113925A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP06758513A EP1928247A4 (en) 2005-04-20 2006-04-20 Composition and use of phyto-percolate for treatment of disease
US12/067,735 US8586053B2 (en) 2005-09-21 2006-04-20 Composition and use of phyto-percolate for treatment of disease
CA002625818A CA2625818A1 (en) 2005-04-20 2006-04-20 Composition and use of phyto-percolate for treatment of disease
US11/606,676 US7807622B2 (en) 2004-04-23 2006-11-30 Composition and use of phyto-percolate for treatment of disease
US12/897,574 US8791060B2 (en) 2004-04-23 2010-10-04 Composition and use of phyto-percolate for treatment of disease
US14/558,516 US10166270B2 (en) 2004-04-23 2014-12-02 Composition and method for affecting cytokines and NF-κB

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
USPCT/US2005/13375 2005-04-20
PCT/US2005/013375 WO2005112987A2 (en) 2004-04-23 2005-04-20 Method of preparation and use of fibrinolytic enzymes in the treatment of disease
US71902505P 2005-09-21 2005-09-21
US60/719,025 2005-09-21
US74177405P 2005-12-02 2005-12-02
US60/741,774 2005-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/013375 Continuation-In-Part WO2005112987A2 (en) 2004-04-23 2005-04-20 Method of preparation and use of fibrinolytic enzymes in the treatment of disease

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2005/013375 Continuation-In-Part WO2005112987A2 (en) 2004-04-23 2005-04-20 Method of preparation and use of fibrinolytic enzymes in the treatment of disease
US11/606,676 Continuation-In-Part US7807622B2 (en) 2004-04-23 2006-11-30 Composition and use of phyto-percolate for treatment of disease
AU2006320264A Division AU2006320264A1 (en) 2005-04-20 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Publications (2)

Publication Number Publication Date
WO2006113925A2 WO2006113925A2 (en) 2006-10-26
WO2006113925A3 true WO2006113925A3 (en) 2007-06-14

Family

ID=37115978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/015302 Ceased WO2006113925A2 (en) 2004-04-23 2006-04-20 Composition and use of phyto-percolate for treatment of disease

Country Status (2)

Country Link
EP (1) EP1928247A4 (en)
WO (1) WO2006113925A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807622B2 (en) 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
US8586053B2 (en) 2005-09-21 2013-11-19 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
WO2008040516A2 (en) * 2006-10-02 2008-04-10 Georg Fritzmeier Gmbh & Co. Kg Microbiological composition and use thereof
CA2827401A1 (en) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents and mechanisms for treating hypercholesterolemia
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
ES2972377T3 (en) 2015-02-16 2024-06-12 Zivo Bioscience Inc Anti-inflammatory and immunomodulatory compositions comprising Klebsormidium and uses thereof
WO2017142906A1 (en) 2016-02-16 2017-08-24 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6723326B1 (en) * 1997-04-18 2004-04-20 Ganeden Biotech, Inc. Topical compositions containing probiotic Bacillus bacteria, spores, and extracellular products and uses thereof
US6733751B2 (en) * 1999-08-26 2004-05-11 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564466A1 (en) * 2004-04-23 2005-12-01 Health Enhancement Products, Inc. Method of preparation and use of fibrinolytic enzymes in the treatment of disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723326B1 (en) * 1997-04-18 2004-04-20 Ganeden Biotech, Inc. Topical compositions containing probiotic Bacillus bacteria, spores, and extracellular products and uses thereof
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6733751B2 (en) * 1999-08-26 2004-05-11 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1928247A4 *

Also Published As

Publication number Publication date
EP1928247A2 (en) 2008-06-11
WO2006113925A2 (en) 2006-10-26
EP1928247A4 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2006097793A3 (en) Compositions capable of facilitating penetration across a biological barrier
WO2007112052A3 (en) Formulations and methods for vascular permeability-related diseases or conditions
WO2007089584A3 (en) Compositions and their uses directed to huntingtin
EP2275543A3 (en) Compositions and their uses directed to hepcidin
WO2008063382A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
MY143795A (en) Tetrahydropyridoindole derivatives
WO2005076979A3 (en) Diagnosis and therapeutics for cancer
WO2005113752A3 (en) Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
WO2008039941A3 (en) Scgb3a2 as a growth factor and anti-apoptotic agent
WO2006128125A3 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
WO2006113925A3 (en) Composition and use of phyto-percolate for treatment of disease
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
WO2004093563A3 (en) Low cholesterol, functional animal muscle protein composition and process
WO2007065024A3 (en) Composition and use of phyto-percolate for treatment of disease
WO2005112987A3 (en) Method of preparation and use of fibrinolytic enzymes in the treatment of disease
WO2008009868A3 (en) Methods and tools for the therapy of neurodegenerative pathologies
WO2006009718A3 (en) Methods for treating or preventing erectile dysfunction or urinary incontinence
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
WO2006053788A3 (en) Alterations in seborrheic keratoses and their applications

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11606676

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006758513

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008532207

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2625818

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP

WWE Wipo information: entry into national phase

Ref document number: 12067735

Country of ref document: US